DRW Securities
SPRY icon

DRW Securities’s ARS Pharmaceuticals SPRY Stock Holding History

DRW Securities’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-43,665
Closed -$351K – 1444
2026
Q1 		$351K Buy
+43,665
New +$418K ﹤0.01% 810
2025
Q4 		– Sell
-35,742
Closed -$349K – 1669
2025
Q3 		$349K Buy
+35,742
New +$513K 0.01% 779

Other funds holding SPRY

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Rubric Capital Management (New York)
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

DRW Securities's SPRY Position: Q2 2026 in Review

DRW Securities sold out of ARS Pharmaceuticals (SPRY) in Q2 2026, closing a stake of 43,665 shares — an estimated $351K sold.

DRW Securities first reported a position in SPRY in Q3 2025 and held it in 2 quarters. The position peaked at $351K in Q1 2026. 208 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • DRW Securities reported no remaining ARS Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • DRW Securities sold 43,665 ARS Pharmaceuticals shares in Q2 2026, an estimated $351K.
  • DRW Securities first reported a position in ARS Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • DRW Securities's ARS Pharmaceuticals position peaked at $351K in Q1 2026.
  • 208 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on DRW Securities's 13F filing for Q2 2026, filed 14 Aug 2026.